原发上呼吸消化道外结外NK/T细胞淋巴瘤的临床特征及生存分析

摘要/Abstract

摘要：

目的分析原发上呼吸消化道外结外NK/T细胞淋巴瘤(EUADT-ENKTCL)患者的临床特征及生存预后情况。方法收集自2000年至2015年SEER数据库登记的779例结外NK/T细胞淋巴瘤(ENKTCL)患者的临床及生存资料,其中原发上呼吸消化道结外NK/T细胞淋巴瘤(UADT-ENKTCL)患者622例,EUADT-ENKTCL患者157例。对EUADT-ENKTCL患者的临床特征、生存情况及预后因素进行分析。结果EUADT-ENKTCL患者中位发病年龄为55岁,男女比例为1.85∶1。相较于UADT-ENKTCL,EUADT-ENKTCL患者中T细胞来源(χ²=18.916,P<0.001)、晚期病变(χ²=63.669,P<0.001)、伴随B症状(χ²=14.657,P=0.001)以及接受单纯化疗(χ²=71.412,P<0.001)更多见。EUADT-ENKTCL可原发于全身不同器官组织,其中皮肤或皮下软组织最多见(38.2%,60/157),其次依次为胃肠道(18.5%,29/157)、肺/胸膜(13.4%,21/157)、睾丸(6.4%,10/157)和眼眶(5.1%,8/157)等。EUADT-ENKTCL患者中位总生存时间(OS)和5年OS率分别为8.0个月和24.0%,明显劣于UADT-ENKTCL患者(31.0个月和43.5%;χ²=32.080,P<0.001)。单因素分析结果提示晚期、肺原发病变的EUADT-ENKTCL患者预后更差,多因素分析证实临床分期是影响OS的预后因素(Ⅲ~Ⅳ期vs.Ⅰ~Ⅱ期,HR=2.078,95%CI为1.335~3.234,P=0.001)。结论EUADT-ENKTCL是一类高度侵袭性疾病,与UADT-NKTCL相比,存在临床特征的差异性且长期生存不理想。

关键词:淋巴瘤,结外NK-T细胞,生存,预后,上消化呼吸道外

Abstract:

ObjectiveTo analyze the clinical characteristics, survival outcome and prognostic factors of patients with extra-upper aerodigestive tract extranodal NK/T-cell lymphoma (EUADT-ENKTCL).MethodsWe collected the clinical data of 779 patients with ENKTCL who were registered in SEER (Surveillance, Epidemiology, and End Results) database from 2000 to 2015 including 622 cases diagnosed with upper-aerodigestive tract extranodal NK/T-cell lymphoma (UADT-ENKTCL) and 157 cases with EUADT-ENKTCL. Clinical characteristics, survival outcome and prognostic factors were analyzed in EUADT-ENKTCL patients.ResultsThe median age of patients with EUADT-ENKTCL was 55. The ratio of male to female was 1.85∶1. Compared with UADT-ENKTCL, patients with EUADT-ENKTCL accounted a higher proportion of malignant T-cell origin (χ²=18.916,P<0.001), advanced stage disease (χ²=63.669,P<0.001), accompanied B symptoms (χ²=14.657,P=0.001) and receiving chemotherapy alone (χ²=71.412,P<0.001). EUADT-ENKTCL could be originated in different organs and tissues throughout the body, among which the skin or subcutaneous soft tissues was the most common locations (38.2%, 60/157), followed by gastrointestinal tract (18.5%, 29/157), lung/pleura (13.4%, 21/157), testis (6.4%, 10/157), orbit (5.1%, 8/157) and others. The median overall survival (OS) was 8.0 months and 5-year OS rate was 24.0% for the EUADT-ENKTCL cohort, which were much inferior to those of UADT-ENKTCL patients (31.0 months and 43.5%;χ²=32.080,P<0.001). Univariate analysis showed that patients with advanced stage or primary lung disease of EUADT-ENKTCL had unfavorable OS. Stage was a prognostic factor of OSviamultivariate analysis (Ⅲ/Ⅳvs. Ⅰ/Ⅱ,HR=2.078, 95%CI: 1.335-3.234,P=0.001).ConclusionEUADT-ENKTCL is a highly aggressive malignancy. Compared with UADT-ENKTCL, EUADT-ENKTCL patients have different clinical characteristics and significantly inferior OS.

Key words:Lymphoma,extranodal NK-T-cell,Survival,Prognosis,Extra-upper aerodigestive tract

齐菲, 董梅. 原发上呼吸消化道外结外NK/T细胞淋巴瘤的临床特征及生存分析[J]. 国际肿瘤学杂志, 2020, 47(3): 157-163.

Qi Fei, Dong Mei. Clinical characteristics and survival analysis of extra-upper aerodigestive tract extranodal NK/T-cell lymphoma[J]. Journal of International Oncology, 2020, 47(3): 157-163.

图/表6

表1

779例结外NK/T细胞淋巴瘤患者临床特征[例(%)]"

临床特征	UADT-ENKTCL 组(n=622)	EUADT-ENKTCL 组(n=157)
年龄(岁)
≤60	398(64.0)	90(57.3)	2.378	0.123
>60	224(36.0)	67(42.8)
性别
女	231(37.1)	55(35.0)	0.239	0.624
男	391(62.9)	102(65.0)
种族
白种人	436(70.1)	112(71.3)
黑种人	23(3.7)	6(3.8)	0.123	0.940
其他	163(26.2)	39(24.8)
细胞起源
NK细胞	459(73.8)	88(56.1)
T细胞	133(21.4)	57(36.3)	18.916	<0.001
其他	30(4.8)	12(7.6)
分期
Ⅰ~Ⅱ期	473(76.0)	72(45.9)
Ⅲ~Ⅳ期	126(20.3)	60(38.2)	63.669	<0.001
不详	23(3.7)	25(15.9)
B症状
无	304(48.9)	51(32.5)
有	240(38.6)	75(49.0)	14.657	0.001
不详	78(12.5)	31(17.8)
治疗模式
无	91(14.6)	40(25.5)
单纯化疗	143(23.0)	77(49.0)	71.412	<0.001
单纯放疗	107(17.2)	16(10.2)
放化疗联合	281(45.2)	24(15.3)

表1

图1

表2

622例原发上呼吸消化道结外NK/T细胞淋巴瘤患者总生存的单因素和多因素分析"

特征	单因素分析				多因素分析
特征	HR值	95%CI	P值		HR值	95%CI	P值
年龄(>60岁vs.≤60岁)	1.432	1.557~1.772	0.001	1.311		1.041~1.650	0.021
性别(男vs.女)	1.070	0.860~1.331	0.543	-		-	-
种族
白种人	1			1
黑种人	2.513	0.994~2.303	0.054	1.346		0.853~2.124	0.202
其他	0.981	0.776~1.267	0.944	0.923		0.721~1.182	0.527
细胞来源(Tvs. NK细胞)	1.173	0.985~1.397	0.073	1.096		0.840~1.429	0.500
分期(Ⅲ~Ⅳvs.Ⅰ~Ⅱ)	2.133	1.693~2.687	<0.001	1.839		1.048~3.228	0.034
B症状(有vs.无)	1.242	1.128~1.368	<0.001	1.115		0.872~1.426	0.386
原发部位(鼻腔外vs.鼻腔)	1.531	1.237~1.895	<0.001	1.427		1.122~1.815	0.004
治疗模式
无	1			1
单纯化疗	1.124	0.817~1.547	0.473	1.076		0.768~1.509	1.076
单纯放疗	0.705	0.493~0.956	0.047	0.838		0.572~1.227	0.363
放化疗联合	0.433	0.316~0.593	<0.001	0.514		0.347~0.719	<0.001

表2

表3

157例原发上呼吸消化道外结外NK/T细胞淋巴瘤患者总生存单因素分析"

特征	HR值	95%CI	P值
年龄(>60岁vs.≤60岁)	1.274	0.900~1.803	0.172
性别(男vs.女)	0.828	0.578~1.187	0.305
种族
白色	1
黑色	0.987	0.362~2.691	0.980
其他	0.914	0.595~1.404	0.682
细胞来源(Tvs. NK细胞)	1.012	0.701~1.460	0.957
分期(Ⅲ~Ⅳvs.Ⅰ~Ⅱ)	1.855	1.259~2.735	0.001
B症状(有vs.无)	1.274	0.834~1.947	0.263
原发部位
皮肤	1
肺	1.692	1.014~2.823	0.044
胃肠道	0.976	0.588~1.620	0.924
睾丸	1.049	0.496~2.218	0.900
眼眶	0.935	0.401~2.181	0.876
治疗模式
无	1
单纯化疗	0.848	0.555~1.298	0.449
单纯放疗	0.824	0.440~1.534	0.545
放化疗联合	0.578	0.325~1.027	0.062

表3

图2

图3

参考文献28

[1]	Tamaru JI . 2016 revision of the WHO classification of lymphoid neoplasms[J]. Rinsho Ketsueki, 2017,58(10):2188-2193. DOI: 10.11406/rinketsu.58.2188.
[2]	Chihara D, Ito H, Matsuda T , et al. Differences in incidence and trends of haematological malignancies in Japan and the United States[J]. Br J Haematol, 2014,164(4):536-545. DOI: 10.1111/bjh.12659. doi:10.1111/bjh.12659
[3]	Sun J, Yang Q, Lu Z , et al. Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification[J]. Am J Clin Pathol, 2012,138(3):429-434. DOI: 10.1309/AJCP7YLTQPUSDQ5C. doi:10.1309/AJCP7YLTQPUSDQ5C
[4]	Haverkos BM, Pan Z, Gru AA , et al. Extranodal NK/T cell lymphoma, nasal type (ENKTL-NT): an update on epidemiology, clinical presentation, and natural history in North American and European cases[J]. Curr Hematol Malig Rep, 2016,11(6):514-527. DOI: 10.1007/s11899-016-0355-9. doi:10.1007/s11899-016-0355-9
[5]	Lee J, Park YH, Kim WS , et al. Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy[J]. Eur J Cancer, 2005,41(10):1402-1408. DOI: 10.1016/j.ejca.2005.03.010. doi:10.1016/j.ejca.2005.03.010
[6]	Liu Z, Bi X, Zhang X , et al. Characteristics, prognostic factors, and survival of patients with NK/T-Cell lymphoma of non-upper aerodigestive tract: a 17-year single-center experience[J]. Cancer Research and Treatment, 2019,51(4):1557-1567. DOI: 10.4143/crt.2018.681. doi:10.4143/crt.2018.681
[7]	Kim TM, Lee SY, Jeon YK , et al. Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group[J]. Ann Oncol, 2008,19(8):1477-1484. DOI: 10.1093/annonc/mdn147. doi:10.1093/annonc/mdn147
[8]	Jo JC, Yoon DH, Kim S , et al. Clinical features and prognostic model for extranasal NK/T-cell lymphoma[J]. Eur J Haematol, 2012,89(2):103-110. DOI: 10.1111/j.1600-0609.2012.01796.x. doi:10.1111/j.1600-0609.2012.01796.x
[9]	林宁晶, 宋玉琴, 郑文 , 等. 非上呼吸消化道原发NK/T细胞淋巴瘤患者的临床特征及生存分析[J]. 中华血液学杂志, 2015,36(1):29-33. DOI: 10.3760/cma.j.issn.0253-2727.2015.01.007. doi:10.3760/cma.j.issn.0253-2727.2015.01.007
[10]	Vose J, Armitage J, Weisenburger D . International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes[J]. J Clin Oncol, 2008,26(25):4124-4130. DOI: 10.1200/JCO.2008.16.4558. doi:10.1200/JCO.2008.16.4558
[11]	Au WY, Weisenburger DD, Intragumtornchai T , et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project[J]. Blood, 2009,113(17):3931-3937. DOI: 10.1182/blood-2008-10-185256. doi:10.1182/blood-2008-10-185256
[12]	Huang JJ, Zhu YJ, Xia Y , et al. A novel prognostic model for extranodal natural killer/T-cell lymphoma[J]. Med Oncol, 2012,29(3):2183-2190. DOI: 10.1007/s12032-011-0030-x. doi:10.1007/s12032-011-0030-x
[13]	Vásquez J, Serrano M, Lopez L , et al. Predictors of survival of natural killer/T-cell lymphoma, nasal type, in a non-Asian population: a single cancer centre experience[J]. Ecancermedicalscience, 2016,10:688. DOI: 10.3332/ecancer.2016.688.
[14]	Tsai HJ, Lin SF, Chen CC , et al. Long-term results of a phase Ⅱ trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphoma[J]. Eur J Haematol, 2015,94(2):130-137. DOI: 10.1111/ejh.12405. doi:10.1111/ejh.2015.94.issue-2
[15]	Qi F, Wang WH, He XH , et al. Phase 2 study of first-line intensity modulated radiation therapy followed by gemcitabine, dexamethasone, and cisplatin for high-risk, early stage extranodal nasal-type NK/T-cell lymphoma: the GREEN study[J]. Int J Radiat Oncol Biol Phys, 2018,102(1):61-70. DOI: 10.1016/j.ijrobp.2018.05.046. doi:10.1016/j.ijrobp.2018.05.046
[16]	Jiang M, Zhang H, Jiang Y , et al. Phase 2 trial of "sandwich" L-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage ⅠE to ⅡE, nasal type, extranodal natural killer/T-cell lymphoma[J]. Cancer, 2012,118(13):3294-3301. DOI: 10.1002/cncr.26629. doi:10.1002/cncr.26629
[17]	Yamaguchi M, Tobinai K, Oguchi M , et al. Phase Ⅰ/Ⅱ study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211[J]. J Clin Oncol, 2009,27(33):5594-5600. DOI: 10.1200/JCO.2009.23.8295. doi:10.1200/JCO.2009.23.8295
[18]	Yoon DH, Kim SJ, Jeong SH , et al. Phase Ⅱ trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage Ⅰ/Ⅱ extranodal NK/T-cell lymphoma, nasal type (CISL-1008)[J]. Oncotarget, 2016,7(51):85584-85591. DOI: 10.18632/oncotarget.11319. doi:10.18632/oncotarget.v7i51
[19]	Kim SJ, Kim K, Kim BS , et al. Phase Ⅱ trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage ⅠE to ⅡE, nasal, extranodal NK/T-cell lymphoma: consortium for improving survival of lymphoma study[J]. J Clin Oncol, 2009,27(35):6027-6032. DOI: 10.1200/JCO.2009.23.8592. doi:10.1200/JCO.2009.23.8592
[20]	Yamaguchi M, Suzuki R, Oguchi M . Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type[J]. Blood, 2018,131(23):2528-2540. DOI: 10.1182/blood-2017-12-791418. doi:10.1182/blood-2017-12-791418
[21]	Kim TM, Park YH, Lee SY , et al. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage Ⅰ(E)/Ⅱ(E) extranodal NK/T-cell lymphoma, nasal type[J]. Blood, 2005,106(12):3785-3790. DOI: 10.1182/blood-2005-05-2056.
[22]	Niu SQ, Yang Y, Li YY , et al. Primary site and regional lymph node involvement are independent prognostic factors for early-stage extranodal nasal-type natural killer/T cell lymphoma[J]. Chin J Cancer, 2016,35:34. DOI: 10.1186/s40880-016-0096-0. doi:10.1186/s40880-016-0096-0
[23]	Yang Y, Zhang YJ, Zhu Y , et al. Prognostic nomogram for overall survival in previously untreated patients with extranodal NK/T-cell lymphoma, nasal-type: a multicenter study[J]. Leukemia, 2015,29(7):1571-1577. DOI: 10.1038/leu.2015.44. doi:10.1038/leu.2015.44
[24]	Yang Y, Zhu Y, Cao JZ , et al. Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study[J]. Blood, 2015,126(12):1424-1432. DOI: 10.1182/blood-2015-04-639336.
[25]	Ding W, Wang J, Zhao S , et al. Clinicopathological study of pulmonary extranodal nature killer/T-cell lymphoma, nasal type and literature review[J]. Pathol Res Pract, 2015,211(7):544-549. DOI: 10.1016/j.prp.2015.04.002. doi:10.1016/j.prp.2015.04.002
[26]	Yu JB, Zuo Z, Tang Y , et al. Extranodal nasal-type natural killer/T-cell lymphoma of the skin: a clinicopathologic study of 16 cases in China[J]. Hum Pathol, 2009,40(6):807-816. DOI: 10.1016/j.humpath.2008.08.020. doi:10.1016/j.humpath.2008.08.020
[27]	Zheng S, Ouyang Q, Li G , et al. Primary intestinal NK/T cell lymphoma: a clinicopathologic study of 25 Chinese cases[J]. Arch Iran Med, 2012,15(1):36-42. DOI: 012151/AIM.0011.
[28]	Cheung MMC, Chan JKC, Lau W , et al. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality[J]. Int J Radiat Oncol Biol Phys, 2002,54(1):182-190. DOI: https://doi.org/10.1016/S0360-3016(02)02916-4.